Research Topics
| Daniel KleinSummaryAffiliation: Kaiser Permanente Country: USA Publications
| Collaborators
|
Detail Information
Publications
Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detectionDaniel Klein
Kaiser Permanente Medical Center, Hayward, California, USA
J Acquir Immune Defic Syndr 32:143-52. 2003..In our setting, effective risk assessment before symptoms arise offers greater potential for raising the mean CD4 cell count at diagnosis than does increased awareness of selected HIV-associated clinical prompts...- Cardiovascular Disease and HIV InfectionDaniel Klein
N Engl J Med 349:1869-70; author reply 1869-70. 2003 - Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?Daniel Klein
Kaiser Permanente Medical Center, Hayward, California, USA
J Acquir Immune Defic Syndr 30:471-7. 2002..Other HIV-related mechanisms may be at work, causing increased CHD and MI risk among all HIV-infected persons... - Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapyChun Chao
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, USA
AIDS 24:1765-70. 2010..uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy... - Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patientsMichael Horberg
HIV Initiative, Kaiser Permanente, 2000 Broadway Oakland, CA 94612, USA
J Acquir Immune Defic Syndr 53:62-9. 2010..To better characterize the long-term effects of tenofovir on renal function in a large managed care organization... - HIV infection and the risk of cancers with and without a known infectious causeMichael J Silverberg
Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
AIDS 23:2337-45. 2009..To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons... - Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER studyWilliam Towner
Department of Internal Medicine, Kaiser Permanente, Los Angeles, CA 90027, USA
J Acquir Immune Defic Syndr 51:367-73. 2009..To determine the safety and efficacy of changing enfuvirtide to raltegravir in HIV-1-infected patients with HIV-1 RNA below the level of quantification for at least 6 months on an enfuvirtide-containing antiretroviral regimen... - Older age and the response to and tolerability of antiretroviral therapyMichael J Silverberg
Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
Arch Intern Med 167:684-91. 2007..The unique health needs of a growing older adult population infected with human immunodeficiency virus (HIV) require study, especially in terms of the response to and tolerability of highly active antiretroviral therapy (HAART)... - Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patientsMichael Horberg
HIV Initiative, Kaiser Permanente, Oakland, California 94612, USA
HIV Clin Trials 9:367-74. 2008..Evaluate responses and safety of ritonavir-boosted atazanavir ("boosted atazanavir") compared to unboosted atazanavir among antiretroviral-naïve patients in the clinical managed care setting... - Response to newly prescribed lipid-lowering therapy in patients with and without HIV infectionMichael J Silverberg
Kaiser Permanente Northern California, Oakland, California, USA
Ann Intern Med 150:301-13. 2009..Antiretroviral agents, particularly protease inhibitors (PIs), may adversely affect lipid levels in patients with HIV infection. However, it is not known whether HIV-associated dyslipidemia is more difficult to treat... - HIV quality performance measures in a large integrated health care systemMichael Horberg
HIV Initiative, Kaiser Permanente, Oakland, California, USA
AIDS Patient Care STDS 25:21-8. 2011..S. rate. These results have implications for improving our care process going forward, as well as for the new U.S. domestic HIV/AIDS Strategy... - Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapyJudith S Currier
Circulation 118:e29-35. 2008 - HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mLYumi Mitsuya
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford 94305, and Kaiser-Permanente Medical Care Program-Northern California, Oakland, CA, USA
J Acquir Immune Defic Syndr 43:56-9. 2006..Genotype validity was confirmed in 49 of 50 patients with a previous or follow-up genotype. The belief that genotypic resistance testing is unreliable in samples with low-level viremia should be reassessed... - HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceSoo-Yon Rhee
Division of Infectious Diseases, Department of Medicine, Stanford University, CA 94301, USA
J Infect Dis 192:456-65. 2005..In contrast, nonpolymorphic treatment-associated mutations may be more sensitive and specific markers of transmitted HIV-1 drug resistance... - Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutationsYumi Mitsuya
Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
J Virol 82:10747-55. 2008.... - Perceptions of human immunodeficiency virus testing services among HIV-positive persons not in medical careMichael Horberg
Sex Transm Dis 33:464; author reply 465. 2006